APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Hypoglycemic Agents and Insulin Analogues

Compare research editions
View pricing & licenses

Selected research

Industry Research

Oral Hypoglycemic Agents and Insulin Analogues Industry Research Report 2026

22 December 2025121 pages

Choose your research edition.

Industry ResearchOral Hypoglycemic Agents and Insulin Analogues Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Hypoglycemic Agents and Insulin Analogues Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Oral Hypoglycemic Agents and Insulin Analogues Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Hypoglycemic Agents and Insulin Analogues Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Hypoglycemic Agents and Insulin Analogues Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Oral Hypoglycemic Agents and Insulin Analogues market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Oral Hypoglycemic Agents and Insulin Analogues is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Oral Hypoglycemic Agents and Insulin Analogues is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Oral Hypoglycemic Agents and Insulin Analogues is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Oral Hypoglycemic Agents and Insulin Analogues include Tonghua Dongbao, Novo Nordisk, Eli Lilly, Jiangsu Wanbang, United Laboratory, Sanofi-Aventis, Ganlee and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Oral Hypoglycemic Agents and Insulin Analogues market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Oral Hypoglycemic Agents and Insulin Analogues Market by Company

Tonghua Dongbao

Novo Nordisk

Eli Lilly

Jiangsu Wanbang

United Laboratory

Sanofi-Aventis

Ganlee

Biocon

Oral Hypoglycemic Agents and Insulin Analogues Segment by Type

Alpha-glucosidase Inhibitors

Insulin Secretagogues

Insulin Sensitizers

Oral Hypoglycemic Agents and Insulin Analogues Segment by Application

Hospitals

Drug Store

Others

Oral Hypoglycemic Agents and Insulin Analogues Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Hypoglycemic Agents and Insulin Analogues market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Hypoglycemic Agents and Insulin Analogues and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Hypoglycemic Agents and Insulin Analogues.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Oral Hypoglycemic Agents and Insulin Analogues manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Oral Hypoglycemic Agents and Insulin Analogues by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Oral Hypoglycemic Agents and Insulin Analogues in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Oral Hypoglycemic Agents and Insulin Analogues Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (k units) of Manufacturers (2021-2026) Table 7. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Manufacturers (2021-2026) Table 8. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue of Manufacturers (2021-2026) Table 9. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Oral Hypoglycemic Agents and Insulin Analogues Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Oral Hypoglycemic Agents and Insulin Analogues Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Product Type & Application Table 14. Global Oral Hypoglycemic Agents and Insulin Analogues Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Oral Hypoglycemic Agents and Insulin Analogues by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Tonghua Dongbao Company Information Table 19. Tonghua Dongbao Business Overview Table 20. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 22. Tonghua Dongbao Recent Developments Table 23. Novo Nordisk Company Information Table 24. Novo Nordisk Business Overview Table 25. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 27. Novo Nordisk Recent Developments Table 28. Eli Lilly Company Information Table 29. Eli Lilly Business Overview Table 30. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 32. Eli Lilly Recent Developments Table 33. Jiangsu Wanbang Company Information Table 34. Jiangsu Wanbang Business Overview Table 35. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 37. Jiangsu Wanbang Recent Developments Table 38. United Laboratory Company Information Table 39. United Laboratory Business Overview Table 40. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 42. United Laboratory Recent Developments Table 43. Sanofi-Aventis Company Information Table 44. Sanofi-Aventis Business Overview Table 45. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 47. Sanofi-Aventis Recent Developments Table 48. Ganlee Company Information Table 49. Ganlee Business Overview Table 50. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 52. Ganlee Recent Developments Table 53. Biocon Company Information Table 54. Biocon Business Overview Table 55. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Biocon Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio Table 57. Biocon Recent Developments Table 58. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2021-2026) & (k units) Table 60. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2021-2026) Table 61. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region (2027-2032) & (k units) Table 62. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Region (2027-2032) Table 63. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2021-2026) Table 65. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Region (2027-2032) Table 67. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 69. North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 70. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 74. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 75. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 79. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 80. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2027-2032) & (US$ Million) Table 82. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 84. South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 85. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (US$ Million) Table 86. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2026) & (k units) Table 89. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2027-2032) & (k units) Table 90. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2027-2032) & (US$ Million) Table 92. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2026) & (k units) Table 93. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2027-2032) & (k units) Table 94. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2021-2026) Table 95. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2027-2032) Table 96. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2021-2026) & (US$ Million) Table 97. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2027-2032) & (US$ Million) Table 98. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2021-2026) Table 99. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2027-2032) Table 100. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2021-2026) & (US$/unit) Table 101. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2027-2032) & (US$/unit) Table 102. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2026) & (k units) Table 103. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2027-2032) & (k units) Table 104. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2021-2026) Table 105. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2027-2032) Table 106. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2021-2026) & (US$ Million) Table 107. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2027-2032) & (US$ Million) Table 108. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2021-2026) Table 109. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2027-2032) Table 110. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2021-2026) & (US$/unit) Table 111. Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2027-2032) & (US$/unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Oral Hypoglycemic Agents and Insulin Analogues Distributors List Table 115. Oral Hypoglycemic Agents and Insulin Analogues Customers List Table 116. Oral Hypoglycemic Agents and Insulin Analogues Industry Trends Table 117. Oral Hypoglycemic Agents and Insulin Analogues Industry Drivers Table 118. Oral Hypoglycemic Agents and Insulin Analogues Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Oral Hypoglycemic Agents and Insulin Analogues Product Image Figure 5. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size (2021-2032) & (US$ Million) Figure 7. Global Oral Hypoglycemic Agents and Insulin Analogues Sales (2021-2032) & (k units) Figure 8. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price (US$/unit) & (2021-2032) Figure 9. Alpha-glucosidase Inhibitors Product Image Figure 10. Insulin Secretagogues Product Image Figure 11. Insulin Sensitizers Product Image Figure 12. Hospitals Product Image Figure 13. Drug Store Product Image Figure 14. Others Product Image Figure 15. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Oral Hypoglycemic Agents and Insulin Analogues Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region in 2025 Figure 21. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region in 2025 Figure 22. North America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country in 2025 Figure 23. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 24. North America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2021-2032) Figure 25. United States Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country in 2025 Figure 29. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 30. Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2021-2032) Figure 31. Germany Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country in 2025 Figure 42. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2021-2032) Figure 44. China Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country in 2025 Figure 53. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 54. South America Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2021-2032) Figure 55. Brazil Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country in 2025 Figure 59. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Country (2021-2032) Figure 61. Egypt Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Oral Hypoglycemic Agents and Insulin Analogues Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2021-2032) Figure 67. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2021-2032) Figure 68. Global Oral Hypoglycemic Agents and Insulin Analogues Price (US$/unit) by Type (2021-2032) Figure 69. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2021-2032) Figure 70. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2021-2032) Figure 71. Global Oral Hypoglycemic Agents and Insulin Analogues Price (US$/unit) by Application (2021-2032) Figure 72. Oral Hypoglycemic Agents and Insulin Analogues Value Chain Figure 73. Oral Hypoglycemic Agents and Insulin Analogues Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Oral Hypoglycemic Agents and Insulin Analogues Industry Opportunities and Challenges

Scope & coverage.

Types
  • Alpha-glucosidase Inhibitors
  • Insulin Secretagogues
  • Insulin Sensitizers
Applications
  • Hospitals
  • Drug Store
  • Others
Companies covered
  • Tonghua Dongbao
  • Novo Nordisk
  • Eli Lilly
  • Jiangsu Wanbang
  • United Laboratory
  • Sanofi-Aventis
  • Ganlee
  • Biocon

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size (2021-2032)
  4. 2.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales (2021-2032)
  5. 2.2.3 Global Oral Hypoglycemic Agents and Insulin Analogues Market Average Price (2021-2032)
  6. 2.3 Oral Hypoglycemic Agents and Insulin Analogues by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Alpha-glucosidase Inhibitors
  9. 2.3.3 Insulin Secretagogues
  10. 2.3.4 Insulin Sensitizers
  11. 2.4 Oral Hypoglycemic Agents and Insulin Analogues by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospitals
  14. 2.4.3 Drug Store
  15. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Oral Hypoglycemic Agents and Insulin Analogues Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Product Type & Application
  8. 3.8 Global Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, Established Date
  9. 3.9 Global Oral Hypoglycemic Agents and Insulin Analogues Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Tonghua Dongbao
  2. 4.1.1 Tonghua Dongbao Company Information
  3. 4.1.2 Tonghua Dongbao Business Overview
  4. 4.1.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  6. 4.1.5 Tonghua Dongbao Recent Developments
  7. 4.2 Novo Nordisk
  8. 4.2.1 Novo Nordisk Company Information
  9. 4.2.2 Novo Nordisk Business Overview
  10. 4.2.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  12. 4.2.5 Novo Nordisk Recent Developments
  13. 4.3 Eli Lilly
  14. 4.3.1 Eli Lilly Company Information
  15. 4.3.2 Eli Lilly Business Overview
  16. 4.3.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  18. 4.3.5 Eli Lilly Recent Developments
  19. 4.4 Jiangsu Wanbang
  20. 4.4.1 Jiangsu Wanbang Company Information
  21. 4.4.2 Jiangsu Wanbang Business Overview
  22. 4.4.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  24. 4.4.5 Jiangsu Wanbang Recent Developments
  25. 4.5 United Laboratory
  26. 4.5.1 United Laboratory Company Information
  27. 4.5.2 United Laboratory Business Overview
  28. 4.5.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  30. 4.5.5 United Laboratory Recent Developments
  31. 4.6 Sanofi-Aventis
  32. 4.6.1 Sanofi-Aventis Company Information
  33. 4.6.2 Sanofi-Aventis Business Overview
  34. 4.6.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  36. 4.6.5 Sanofi-Aventis Recent Developments
  37. 4.7 Ganlee
  38. 4.7.1 Ganlee Company Information
  39. 4.7.2 Ganlee Business Overview
  40. 4.7.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  42. 4.7.5 Ganlee Recent Developments
  43. 4.8 Biocon
  44. 4.8.1 Biocon Company Information
  45. 4.8.2 Biocon Business Overview
  46. 4.8.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Biocon Oral Hypoglycemic Agents and Insulin Analogues Product Portfolio
  48. 4.8.5 Biocon Recent Developments
5 Global Oral Hypoglycemic Agents and Insulin Analogues Market Scenario by Region
  1. 5.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2021-2032
  3. 5.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2021-2026
  4. 5.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Region: 2027-2032
  5. 5.3 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2021-2032
  6. 5.3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2021-2026
  7. 5.3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Region: 2027-2032
  8. 5.4 North America Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country
  9. 5.4.1 North America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  11. 5.4.3 North America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country
  16. 5.5.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  18. 5.5.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country
  41. 5.7.1 South America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  43. 5.7.3 South America Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2032)
  2. 6.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Type (2021-2032)
  4. 6.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Type (2021-2032)
  5. 6.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2032)
  2. 7.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Market Share by Application (2021-2032)
  4. 7.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Application (2021-2032)
  5. 7.2.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Oral Hypoglycemic Agents and Insulin Analogues Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Oral Hypoglycemic Agents and Insulin Analogues Value Chain Analysis
  2. 8.1.1 Oral Hypoglycemic Agents and Insulin Analogues Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Oral Hypoglycemic Agents and Insulin Analogues Production Mode & Process
  5. 8.2 Oral Hypoglycemic Agents and Insulin Analogues Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Oral Hypoglycemic Agents and Insulin Analogues Distributors
  8. 8.2.3 Oral Hypoglycemic Agents and Insulin Analogues Customers
9 Global Oral Hypoglycemic Agents and Insulin Analogues Analyzing Market Dynamics
  1. 9.1 Oral Hypoglycemic Agents and Insulin Analogues Industry Trends
  2. 9.2 Oral Hypoglycemic Agents and Insulin Analogues Industry Drivers
  3. 9.3 Oral Hypoglycemic Agents and Insulin Analogues Industry Opportunities and Challenges
  4. 9.4 Oral Hypoglycemic Agents and Insulin Analogues Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst